Compare Axogen Inc (AXGN) vs D R Horton Inc (DHI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Axogen Inc vs D R Horton Inc — how do they compare? Axogen Inc trades at $49.66 (market cap $2.61B), while D R Horton Inc trades at $150.79 (market cap $42.18B). The key difference: D R Horton Inc is far larger — about 16.2× Axogen Inc's market cap, and D R Horton Inc pays a 1.19% dividend while Axogen Inc pays none. Which is the better fit depends on your goals.
| AXGN | DHI | |
|---|---|---|
Market Cap | $2.61B | $42.18B |
Sector | Technology | Consumer Cyclical |
52-Week High | $48.48 | $184.04 |
52-Week Low | $14.16 | $132.53 |
Enterprise Value | $2.52B | $47.28B |
Dividend Yield | — | 1.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AXGN trades at $49.10, up 1.82% with strong technical momentum and bullish analyst sentiment. The stock shows robust revenue growth (23.1% in Q2 2026) and raised full-year guidance to $279 million, though profitability remains negative with a -13.36% net margin. Technical indicators show overbought RSI levels but strong moving average support, while institutional ownership and analyst consensus (84% buy ratings) signal confidence in the company's nerve care platform expansion.
The outlook remains positive given strong revenue momentum and regulatory advantages, but investors face execution risks from persistent losses and high valuation multiples. Upside potential exists toward the $54.33 consensus target if margin improvements materialize, though volatility may persist near current resistance levels.
DHI trades at $146.49, down slightly by 0.12% today, with a bullish technical signal from moving averages. The company reported Q2 2026 EPS of $3.20, beating estimates, but revenue guidance for FY2026 was lowered. Valuation ratios appear reasonable with a P/E of 14.37 and P/S of 1.31. Operating cash flow remains strong at $3.42B for 2025, though net cash flow was negative due to significant financing outflows.
The outlook is mixed; disciplined execution supports margins, but weak housing demand and elevated mortgage rates pose headwinds. Analyst consensus is a Buy with a $153 target, offering modest upside. Key risks include persistent affordability pressures and competitive threats from disruptors like Boxabl.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Axogen Inc
Axogen is a leader in peripheral nerve regeneration and repair. It provides innovative surgical solutions and clinically proven products, like nerve grafts, to help restore function and quality of life for patients.
Read more on AXGN →About D R Horton Inc
D.R. Horton is a leading homebuilder in the United States with operations in 98 markets across 31 states. D.R. Horton mainly builds single-family detached homes (over 90% of home sales revenue) and offers products to entry-level, move-up, luxury buyers, and active adults. The company offers homebuyers mortgage financing and title agency services through its financial services segment. D.R. Horton's headquarters are in Arlington, Texas, and it manages six regional segments across the United States.
Read more on DHI →
